Neo Ivy Capital Management Purchases Shares of 701 FibroGen Inc (NASDAQ:FGEN)

Deane Yancy 2020-03-12 19:03

Neo Ivy Capital Management acquired a new position in shares of FibroGen Inc (NASDAQ:FGEN) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 701 shares of the biopharmaceutical company’s stock, valued at approximately $30,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of FGEN. Victory Capital Management Inc. lifted its stake in shares of FibroGen by 2.3% in the fourth quarter. Victory Capital Management Inc. now owns 12,059 shares of the biopharmaceutical company’s stock valued at $505,000 after buying an additional 270 shares in the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in shares of FibroGen by 2.6% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 11,438 shares of the biopharmaceutical company’s stock valued at $491,000 after purchasing an additional 288 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of FibroGen by 11.1% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,249 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 523 shares in the last quarter. Metropolitan Life Insurance Co NY lifted its position in shares of FibroGen by 4.6% during the third quarter. Metropolitan Life Insurance Co NY now owns 25,234 shares of the biopharmaceutical company’s stock valued at $933,000 after purchasing an additional 1,106 shares in the last quarter. Finally, Bailard Inc. lifted its position in shares of FibroGen by 12.7% during the fourth quarter. Bailard Inc. now owns 10,143 shares of the biopharmaceutical company’s stock valued at $435,000 after purchasing an additional 1,143 shares in the last quarter. Institutional investors own 69.73% of the company’s stock.

Shares of FGEN traded down $4.60 during trading hours on Thursday, hitting $30.90. The company’s stock had a trading volume of 94,497 shares, compared to its average volume of 664,170. The company has a market cap of $2.98 billion, a price-to-earnings ratio of -32.19 and a beta of 1.77. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.84 and a quick ratio of 6.77. The business has a 50 day simple moving average of $42.91 and a two-hundred day simple moving average of $41.82. FibroGen Inc has a 52-week low of $32.33 and a 52-week high of $58.00.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Monday, March 2nd. The biopharmaceutical company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.53). The business had revenue of $7.97 million during the quarter, compared to analysts’ expectations of $40.32 million. FibroGen had a negative return on equity of 13.35% and a negative net margin of 30.00%. FibroGen’s revenue for the quarter was down 92.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.23 EPS. Research analysts predict that FibroGen Inc will post -1.12 earnings per share for the current year.

In other FibroGen news, SVP Christine Chung sold 5,625 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $42.98, for a total value of $241,762.50. Following the completion of the transaction, the senior vice president now owns 138,269 shares of the company’s stock, valued at approximately $5,942,801.62. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Kalevi Kurkijarvi sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $42.66, for a total transaction of $255,960.00. Following the completion of the transaction, the director now directly owns 34,400 shares of the company’s stock, valued at approximately $1,467,504. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 32,295 shares of company stock valued at $1,436,971. 8.96% of the stock is owned by corporate insiders.

Several analysts have commented on the stock. BidaskClub raised shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Wednesday, February 5th. Zacks Investment Research lowered shares of FibroGen from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 14th. Mizuho reaffirmed a “buy” rating and issued a $72.00 price objective on shares of FibroGen in a research report on Thursday, February 13th. Finally, ValuEngine raised shares of FibroGen from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $51.25.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.